ipatasertib   Click here for help

GtoPdb Ligand ID: 7887

Synonyms: GDC-0068
PDB Ligand
Compound class: Synthetic organic
Comment: Ipatasertib is an inhibitor of the AKT family of protein kinases [1]. The synthesis of ipatasertib is described in patent WO2008006040 [2] and [1] where it is compound 28 (the Supporting Information for this article contains activity data for compound 28 against a full kinase screening panel). This compound is also represented on PubChem by CID 23649210.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 81.59
Molecular weight 457.22
XLogP 2.75
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CC(NCC(C(=O)N1CCN(CC1)c1ncnc2c1C(C)CC2O)c1ccc(cc1)Cl)C
Isomeric SMILES CC(NC[C@@H](C(=O)N1CCN(CC1)c1ncnc2c1[C@H](C)C[C@H]2O)c1ccc(cc1)Cl)C
InChI InChI=1S/C24H32ClN5O2/c1-15(2)26-13-19(17-4-6-18(25)7-5-17)24(32)30-10-8-29(9-11-30)23-21-16(3)12-20(31)22(21)27-14-28-23/h4-7,14-16,19-20,26,31H,8-13H2,1-3H3/t16-,19-,20-/m1/s1
No information available.
Summary of Clinical Use Click here for help
Ipatasertib has progressed to Phase 2 clinical evaluation (as of October 2018) for several oncological indications. Click here to link to ClinicalTrials.gov's full list of ipatasertib trials.